Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 June 2019Website:
http://immunovant.comNext earnings report:
12 February 2025Last dividends:
N/ANext dividends:
N/APrice
pre-market | 18 min agoDividend
Analysts recommendations
Institutional Ownership
IMVT Latest News
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options.
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024.
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024.
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
On Wall Street, analysts have set an average price target for Immunovant (IMVT) that suggests a potential increase of 68.6%. Although the reliability of this metric is uncertain, the positive trend in earnings estimates could lead to a rise in the stock price.
There is increasing optimism about Immunovant's earnings prospects, leading to its upgrade to a Zacks Rank #2 (Buy) and potentially causing the stock to rise.
Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advancing toward registrational trials. Financial health appears strong with a 40-month cash runway, but increased R&D could affect this.
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?
- 1(current)
What type of business is Immunovant?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
What sector is Immunovant in?
Immunovant is in the Healthcare sector
What industry is Immunovant in?
Immunovant is in the Biotechnology industry
What country is Immunovant from?
Immunovant is headquartered in United States
When did Immunovant go public?
Immunovant initial public offering (IPO) was on 21 June 2019
What is Immunovant website?
https://immunovant.com
Is Immunovant in the S&P 500?
No, Immunovant is not included in the S&P 500 index
Is Immunovant in the NASDAQ 100?
No, Immunovant is not included in the NASDAQ 100 index
Is Immunovant in the Dow Jones?
No, Immunovant is not included in the Dow Jones index
When was Immunovant the previous earnings report?
No data
When does Immunovant earnings report?
The next expected earnings date for Immunovant is 12 February 2025